🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — August 11, 2026

The August 11, 2026 small-cap biotech digest captures four FALLBACK-type approvals, all classified as 'Other' and yielding neutral signals; there were zero NMEs, zero true biosimilars, and zero label expansions. The period highlights a quiet regulatory cadence from small-cap sponsors Baxter Healthcare Corp, Ascent Pharmaceuticals Inc, Umedica, and Fresenius Kabi USA, all for off-patent generics (levetiracetam, an unknown product, ranolazine, and nicardipine hydrochloride). No investment-grade upside or downside catalysts emerged: these approvals signal market standard generic entries without breakthrough, orphan, or accelerated designation perks. The highest-conviction neutral event is the entry of Fresenius Kabi's nicardipine hydrochloride—a hospital-based vasodilator—which underscores marginal pricing pressure in institutional generic markets but no material commercial shift. Key watch item: the lack of NMEs and biosimilars in this period highlights the absence of differentiated pipeline catalysts for the indicated small-cap sponsors.

4 total filings
· daily

New Drug Approvals (Original) — August 11, 2026

During the period of August 4-11, 2026, the FDA approved four biosimilar/generic drugs, all classified as FALLBACK approvals with neutral signals. No NMEs, biosimilars, or label expansions were approved, resulting in a low-catalyst week for investors. The approvals include LEVETIRACETAM (BAXTER HLTHCARE CORP), an unknown drug from ASCENT PHARMS INC, RANOLAZINE (UMEDICA), and NICARDIPINE HYDROCHLORIDE (FRESENIUS KABI USA), all targeting established markets with no disclosed peak sales or exclusivity data. The dominant theme is the continued commoditization of mature therapeutic areas, with no high-conviction signals for new commercial opportunities. Key risks include potential pricing erosion for originator drugs in these categories, but the lack of specific commercial details limits actionable insights.

4 total filings
· daily

Defense Manufacturing Contracts — August 11, 2026

The sole contract in this digest is a $139.8M firm-fixed-price award from NASA Goddard Space Flight Center to LANTERIS SPACE LLC for spacecraft bus manufacturing and on-orbit refueling services under the Restore-L mission, spanning 2016-2027. This is a civilian (NASA) contract with no defense component, reflecting continued investment in space servicing technology. The highest-conviction signal is the stable revenue base for LANTERIS SPACE, with $69M already outlayed, but the lack of public financial data limits tradable investment implications. Key risk includes execution risk on the fixed-price structure and potential policy sensitivity due to foreign ownership in a sensitive space program. Watch for NASA's Restore-L milestones and any follow-on contracts in space servicing.

1 total filings
· daily

VA Healthcare & Services Contracts — August 11, 2026

This digest covers a single $129.5 million civilian contract from the Department of Veterans Affairs awarded to Leidos Holdings, Inc. (via QTC Medical Services Inc) for medical disability examinations in the Pacific region. The contract is entirely non-defense, firm-fixed-price, and 85% complete ($110.7 million already outlaid), indicating strong near-term cash conversion but limited forward revenue visibility due to its one-year duration. The highest-conviction signal is the neutral rating, reflecting a fully executed contract with low execution risk but no catalyst for future growth. A key watch item is the potential re-competition for the Pacific region contract, which could threaten Leidos’s incumbent position.

1 total filings
· daily

New Federal Contractors — August 11, 2026

This digest covers two civilian agency contracts totaling $269.3 million, with zero defense-related awards, underscoring a non-defense procurement focus. The dominant theme is NASA's investment in space servicing infrastructure, led by LANTERIS SPACE LLC's $139.8 million fixed-price contract for the Restore-L mission, which signals strategic positioning in on-orbit refueling but carries execution risk due to its long duration and foreign ownership. The second award, a $129.5 million VA medical disability exam contract to Leidos Holdings (via QTC Medical Services), is nearly 85% complete, offering strong cash flow visibility but limited forward revenue. The highest-conviction signal is the NASA contract's technological moat in spacecraft bus manufacturing, though its private-entity status limits direct investment exposure. Key risks include potential policy changes affecting foreign-owned contractors in sensitive space programs and the VA contract's one-year performance period creating re-compete uncertainty.

2 total filings
· daily

Significant Contract Modifications ($10M+) — August 11, 2026

Over the period of August 11, 2026, two significant contract modifications totaling $269.3 million were awarded, both to civilian agencies (NASA and the Department of Veterans Affairs), with zero defense-related contracts. The dominant theme is stable, mandated civilian spending, with the VA contract for medical disability exams (Leidos Holdings) showing near-complete execution and strong cash conversion, while the NASA contract (Lanternis Space LLC) represents a long-duration, high-tech space servicing program with execution risk. The highest-conviction signal is the low-risk, high-cash-flow VA contract for Leidos, though it is a one-year award with limited forward visibility. A key risk is the long performance period and fixed-price nature of the NASA contract, which could pressure margins if technical challenges arise.

2 total filings
· daily

Contract Deobligations Alert — August 11, 2026

The two contracts analyzed total $269.3M in obligations, both from civilian agencies (NASA and VA), with zero defense-related awards. The dominant theme is stable, high-certainty cash flows from government services, with Leidos Holdings (via QTC Medical Services) showing an 85% outlay rate on a $129.5M VA contract, indicating near-complete execution and strong cash conversion. The highest-conviction signal is the Leidos contract's low execution risk, though its one-year duration limits forward revenue visibility. Key risk is the foreign-owned status of LANTERIS SPACE LLC on a sensitive NASA space servicing contract, which could face policy headwinds despite its technological positioning.

2 total filings
· daily

Contract Option Exercises — August 11, 2026

Across these two civilian agency contracts totaling $269.3 million, NASA's Restore-L mission contract with LANTERIS SPACE LLC ($139.8M) and the VA's medical disability exam delivery order with Leidos Holdings subsidiary QTC Medical Services ($129.5M) both signal stable, execution-phase revenue streams with low remaining risk. The 0/2 defense split highlights exclusive civilian sector exposure, with the VA contract nearing 85% completion and the LANTERIS contract having $69M already outlaid. The highest-conviction signal is the VA contract's high outlay rate, confirming near-complete cash conversion for Leidos. Key risks include LANTERIS's foreign ownership status in a sensitive space program and the VA contract's single-year performance period limiting forward visibility.

2 total filings
· daily

NASA & Space Contracts Intelligence — August 11, 2026

This digest covers a single $139.8M NASA contract awarded to LANTERIS SPACE LLC for spacecraft bus design and on-orbit refueling services under the Restore-L mission. The contract is entirely civilian (0% defense-related) and spans a 10+ year performance period through 2027, with $69M already outlayed. The neutral signal (5/10 strength) reflects limited investment implications due to LANTERIS SPACE's private status, though the firm-fixed-price structure and foreign-owned status introduce execution and regulatory risks. Key watch items include Restore-L mission milestones and potential policy shifts on foreign contractors in sensitive space programs.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — August 11, 2026

This digest covers two civilian agency contracts totaling $269.3 million, with zero defense-related awards, highlighting a non-defense procurement focus. The dominant theme is NASA’s investment in on-orbit servicing via LANTERIS SPACE LLC’s $139.8M firm-fixed-price contract for the Restore-L mission, which signals technological capability but carries execution risk over a 10-year period. The second contract, a $129.5M VA medical disability exam award to Leidos Holdings (via QTC Medical Services), is substantially complete with 85% outlay, offering low forward revenue visibility. The highest-conviction signal is the VA contract’s strong cash conversion, while the key risk is LANTERIS SPACE’s foreign-owned status in a sensitive space program. Neutral signals dominate, with no bullish or bearish extremes.

2 total filings
· daily

High-Value Federal Grants ($5M+) — August 11, 2026

This digest covers two high-value civilian contracts totaling $269.3 million, with zero defense exposure. The dominant theme is NASA's strategic investment in on-orbit servicing, led by LANTERIS SPACE LLC's $139.8M firm-fixed-price contract for the Restore-L mission, which signals a long-term government commitment to space infrastructure but carries execution risk due to its 10-year performance period. The second award, a $129.5M VA medical disability exam contract to Leidos Holdings (via QTC Medical Services Inc), is substantially complete (85% outlayed), providing a strong but near-term cash flow event. The highest-conviction signal is the NASA contract's demonstration of technological capability in spacecraft bus manufacturing, though the lack of public financial data on LANTERIS SPACE limits direct investment actionability. Key risks include the fixed-price nature of both contracts transferring cost risk to contractors, and the VA contract's one-year duration creating limited forward revenue visibility for Leidos.

2 total filings
· daily

General Federal Contracts — August 11, 2026

The two contracts analyzed total $269.3M in obligations, both awarded by civilian agencies (NASA and VA) with zero defense-related content, underscoring a non-DOD procurement theme. The highest-conviction signal is Leidos Holdings' $129.5M VA medical disability exam contract, which is 85% outlaid, indicating strong cash conversion and low execution risk. The $139.8M NASA Restore-L contract to LANTERIS SPACE LLC carries medium pricing risk due to its firm-fixed-price structure and foreign-owned status, though partial execution reduces future exposure. Key risks include LANTERIS SPACE's foreign ownership in a sensitive space program and the VA contract's one-year duration limiting forward revenue visibility. Investors should monitor NASA's Restore-L mission milestones and potential follow-on VA contracts for Leidos.

2 total filings
· daily

All NASA Contracts — August 11, 2026

This digest covers a single NASA contract awarded to LANTERIS SPACE LLC valued at $139.8M, representing a civilian space agency investment with no defense-related content. The contract, a firm-fixed-price award for spacecraft bus design and on-orbit refueling services under the Restore-L mission, signals NASA's sustained commitment to space servicing technology but carries medium execution risk due to the fixed-price structure and long performance period. The highest-conviction signal is the neutral competitive win for a foreign-owned entity in a sensitive NASA program, which may face policy headwinds. Key risks include potential cost overruns on the fixed-price contract and regulatory scrutiny of foreign ownership in U.S. space programs.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 11, 2026

The 16 filings from the S&P 500 Technology sector for August 11, 2026, are dominated by insider transactions from two major companies: ServiceNow and Advanced Micro Devices (AMD). A clear pattern of 'tax-withholding' insider activity emerges, where executives exercise stock options and immediately have shares withheld to cover tax liabilities, resulting in net-zero cash flow to the insider but a reduction in their overall share count. This is a routine, non-discretionary activity that does not signal a change in management conviction. However, a notable exception is found at KLA Corporation, where two executives executed pre-planned (10b5-1) open-market sales, which carries a mildly negative signal. The filings lack any period-over-period financial comparisons, forward-looking guidance, or capital allocation announcements, limiting the depth of trend analysis. The primary actionable insight is the contrast between the routine, neutral insider activity at AMD and ServiceNow versus the pre-planned sales at KLA, suggesting a slightly more cautious posture from KLA's management. The overall sector sentiment from these filings is neutral, with no major bullish or bearish catalysts identified.

16 high priority 16 total filings
· daily

Nasdaq 100 Stocks SEC Filings — August 11, 2026

The August 11, 2026 filings for the NASDAQ-100 stream reveal a cluster of insider transactions at Advanced Micro Devices (AMD), with seven executives exercising stock options and selling shares to cover taxes, totaling approximately $10.4 million in sales at $483.36 per share. This pattern, while routine, suggests a potential liquidity event or a lack of immediate bullish conviction among AMD's leadership. In contrast, CoreWeave's COO sold $1.25 million in stock, and Intuitive Surgical's director sold shares under a 10b5-1 plan, both indicating possible caution. Alphabet's Sergey Brin engaged in large-scale gifting of shares, which may signal estate planning rather than a negative outlook. Gilead Sciences and ARM Holdings reported minor insider transactions with no significant directional signal. No forward-looking guidance or period-over-period financial comparisons were disclosed in these filings, limiting trend analysis. The overall sentiment is neutral, with no major bullish or bearish catalysts identified from the insider activity alone. Investors should monitor upcoming earnings calls and any further insider selling for clearer signals.

12 high priority 2 medium 14 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — August 11, 2026

This digest of 50 regulatory filings reveals a landscape dominated by passive institutional investors, with a few high-conviction activist and strategic transactions. The most critical development is the proposed acquisition of ReNew Energy Global plc by a consortium led by CPPIB and its founder at $7.02 per share, a high-materiality event with a tight deadline for the transaction agreement. Activist pressure is evident at Tivic Health Systems, where a major shareholder is demanding CEO termination and board changes as a condition for a $9 million investment. A notable trend is the accumulation of shares in closed-end funds, with SIT Investment Associates building a 29.9% stake in MFS Intermediate Income Trust, just under the 30% threshold. Conversely, several filings show complete exits or reductions, such as Hoak Public Equities exiting Turtle Beach Corp and Granahan Investment Management trimming its Digital Turbine position. The data also highlights a cluster of filings from M3 Partners, LP, which holds passive stakes across multiple small-cap financials, and Donald Smith & Co., which has established new positions in several value-oriented companies. Overall, the filings suggest a market with selective activist engagement, significant passive index and institutional flows, and a few high-stakes corporate control events.

8 high priority 42 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — August 11, 2026

The nine filings for the S&P 500 Financials stream reveal a sector dominated by capital returns and cautious insider sentiment. Berkshire Hathaway's Q2 2026 earnings more than doubled YoY, driven by $12.7B in investment gains, though operating earnings grew a more modest 16.4% and insurance underwriting income declined. Insider selling was a prominent theme, with senior executives at Capital One, Allstate, and JPMorgan Chase collectively disposing of over $9M in stock, while a 10% owner of a Robinhood Ventures fund also sold shares under a 10b5-1 plan. Capital allocation was mixed: Berkshire aggressively repurchased $4.5B in stock, while Goldman Sachs eliminated a preferred stock series after full redemption. The period-over-period data shows a bifurcation between strong investment-driven earnings (Berkshire) and operational headwinds in insurance, with no revenue growth reported across the sample. The most critical development is the concentration of insider selling at major financial institutions, which may signal management caution on near-term valuations or sector outlook.

5 high priority 4 medium 9 total filings
· daily

S&P 500 Energy Sector SEC Filings — August 11, 2026

The four filings for the S&P 500 Energy sector reveal a stark contrast between corporate governance stability and insider sentiment. ConocoPhillips' planned leadership succession, with a 14-year CEO retiring and a CFO stepping up, signals a strategic transition but lacks immediate financial catalysts. Meanwhile, Phillips 66 shows a clear bearish signal from two senior insiders (a Director and the SVP/Controller) who collectively sold over $750K in stock, with the Controller exercising options and immediately selling the shares—a classic red flag. Texas Pacific Land Corp saw a nominal insider purchase, but its materiality is negligible. No period-over-period financial trends, guidance changes, or capital allocation updates were present in any filing, limiting the ability to assess sector-wide growth or margin trends. The key takeaway is that insider selling at Phillips 66, combined with the absence of bullish catalysts elsewhere, creates a cautious near-term outlook for the energy sector.

4 high priority 4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — August 11, 2026

The three filings from Coca-Cola and McCormick & Co. within the S&P 500 Consumer Staples sector present a picture of executive-level capital movements but with contrasting signals. Coca-Cola's insider, Ray Sanket, executed a notable sale of $861K in stock, generating a negative sentiment signal that warrants monitoring for further insider distribution patterns. In contrast, McCormick & Co. saw two key executives—the Chairman, President & CEO and the Chief Human Relations Officer—awarded phantom stock, reflecting retention-based compensation with neutral sentiment. With only three filings and limited period-over-period or forward-looking enriched data available, no overarching sector-wide trends or portfolio-level patterns emerged. The most critical development is the insider sale at Coca-Cola, which, while not large relative to total holdings, could indicate a personal liquidity event or a subtle bearish view by a senior figure. Investors should watch for follow-on insider activity at Coca-Cola and any upcoming earnings calls from both companies to contextualize these transactions.

3 high priority 3 total filings
· daily

US Material Events SEC 8-K Filings — August 11, 2026

This batch of 50 filings reveals a market bifurcated between aggressive capital deployment and acute financial distress. The most significant themes are a surge in M&A and strategic acquisitions (IES Holdings, National CineMedia, Ferguson Enterprises) alongside a wave of refinancing and liability management (Tyson Foods, Griffon, Superior Group). Conversely, several companies are in severe distress, with BioXcel Therapeutics facing an 11-day deadline to avoid default and JBS N.V. reporting a swing to a net loss despite higher sales. Leadership transitions are widespread, with notable CEO successions at ConocoPhillips and B&G Foods, while insider selling patterns are absent from the data. Capital allocation is polarized; some firms are raising debt for growth (Arbor Realty Trust) while others are pausing shareholder returns to de-lever (National CineMedia). The overall picture is one of a market where strong balance sheets are being used offensively, while weaker players are fighting for survival, creating a clear 'haves vs. have-nots' dynamic.

50 high priority 50 total filings